London, UK-based Vicebio raised $100 million in a Series B that will help to fund the development of its Molecular Clamp ...

Obesity-drug developer BioAge Labs Inc. gained about 20% after its initial public offering on Thursday, while natural-gas ...

The U.S. IPO market has bounced back strongly in 2024 after a nearly two-year dry spell, driven by receding recession fears ...

The U.S. IPO market has experienced a significant resurgence in 2024 following nearly two years of stagnation. This recovery is largely due to reduced recession fears and a robust stock market rally.

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

Obesity-drug developer BioAge Labs Inc. gained nearly 30% after its initial public offering on Thursday, while natural-gas producer BKV Inc.'s rose about 3% over its $18 IPO price. BioAge (BIOA) stock ...

BioAge Labs (BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Read more here.

Soaring demand for weight-loss drugs, expected to be a $150 billion market by early 2030s, has attracted more investors toward companies tapping into the lucrative market. The debut valued BioAge at ...

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.

(Reuters) - Shares of BKV rose 3.1% in their debut on the New York Stock Exchange on Thursday, giving the U.S. natural gas ...

BioAge Labs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, visits the Nasdaq ...